Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01473069 · ClinicalTrials.gov registry record · Phase 1
Two Week Study Evaluating Safety, Tolerability and Pharmacokinetics of Multiple Doses of JTK-853 in Healthy Subjects
A Phase 1 study, sponsored by Akros Pharma.
- Terminated
- Registry status
- Phase 1
- Development phase
- 41
- Enrollment target
NCT01473069 is a Phase 1 study that was terminated before completion, run by Akros Pharma. The registered enrollment target is 41 participants.
The verdict
NCT01473069, a Phase 1 study, was terminated before completion, sponsored by Akros Pharma.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 41 participants
- Enrollment target
Study Summary
The purpose of this study was to determine the safety, tolerability and pharmacokinetics of sequential ascending doses of JTK-853 administered for 14 days in healthy subjects and also to determine the effect of a single dose of ketoconazole on the steady-state pharmacokinetic profile of JTK-853 and its metabolite M2 (one cohort only).
Interventions
- DRUG JTK-853 or Placebo
- DRUG JTK-853, ketoconazole
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 41 participants |
| Start Date | 2010-03 |
| Est. Completion | 2010-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01473069
The ClinicalTrials.gov registry entry for NCT01473069 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 41 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Akros Pharma, which has 18 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which JTK-853 or Placebo is the first listed.
NCT01473069 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01473069 about?
NCT01473069 is a clinical study titled "Two Week Study Evaluating Safety, Tolerability and Pharmacokinetics of Multiple Doses of JTK-853 in Healthy Subjects". The purpose of this study was to determine the safety, tolerability and pharmacokinetics of sequential ascending doses of JTK-853 administered for 14 days in healthy subjects and also to determine the effect of a single dose of ketoconazole on the steady-state pharmacokinetic profile of JTK-853 and ...
What is the current status of trial NCT01473069?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 41 participants. The study started on 2010-03. Estimated completion is 2010-07.
What interventions are being tested in trial NCT01473069?
The interventions under investigation include: JTK-853 or Placebo (DRUG), JTK-853, ketoconazole (DRUG).
Who is sponsoring clinical trial NCT01473069?
This trial is sponsored by Akros Pharma, which has 18 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.